Publications by authors named "G King"

Shiga toxin-producing (STEC) is a group of bacteria that causes gastrointestinal illness and occasionally causes large foodborne outbreaks. It represents a major public health concern due to its ability to cause severe illness which can sometimes be fatal. This study was undertaken as part of a rapid investigation into a national foodborne outbreak of STEC O145.

View Article and Find Full Text PDF

Purpose: To explore the negative emotions expressed by parents of children with disabilities when describing their experiences with pediatric health care.

Methods: Quotes mentioning negative emotional experiences and the situations in which these arose were identified in 13 transcribed focus group conversations involving 65 Canadian parents of children with neurodevelopmental disabilities. Data were analyzed using content analysis.

View Article and Find Full Text PDF

Plastids represent promising targets in plant genetic engineering for many biotech applications, ranging from their use as bioreactors for the overproduction of valuable molecules to the installation of transgenes for improving plant traits. For over 30 years, routine methods of plastid transformation have relied on homologous recombination integrating vectors. However, nonintegrating episomal plasmids have recently received more attention as an innovative tool for the plastid genetic engineering of plant cells.

View Article and Find Full Text PDF

Purpose: SWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs).

Methods: Patients with newly diagnosed locally advanced unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) and gallbladder carcinoma (GBC), were randomly assigned 2:1 to either GAP (gemcitabine 800 mg/m, cisplatin 25 mg/m, and nab-paclitaxel 100 mg/m intravenously once per day on days 1 and 8 of a 21-day cycle) or GC (gemcitabine 1,000 mg/m and cisplatin 25 mg/m intravenously once per day on days 1 and 8 of a 21-day cycle).

Results: Among 452 randomly assigned participants, 441 were eligible and analyzable, 67% with ICC, 16% with GBC, and 17% with ECC.

View Article and Find Full Text PDF

We present quantum Monte Carlo calculations of magnetic form factors in A=6-10 nuclei, based on Norfolk two- and three-nucleon interactions, and associated one- and two-body electromagnetic currents. Agreement with the available experimental data for ^{6}Li, ^{7}Li, ^{9}Be, and ^{10}B up to values of momentum transfer q∼3  fm^{-1} is achieved when two-nucleon currents are accounted for. We present a set of predictions for the magnetic form factors of ^{7}Be, ^{8}Li, ^{9}Li, and ^{9}C.

View Article and Find Full Text PDF